Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.

A small proportion of human T-cell leukemia virus type-1 (HTLV-1)-infected individuals develop adult T-cell leukemia/lymphoma, a chemotherapy-resistant lymphoproliferative disease with a poor prognosis. HTLV-1-specific cytotoxic T lymphocytes (CTLs), potential anti-tumor/virus effectors, are impaire...

Full description

Bibliographic Details
Main Authors: Atsuhiko Hasegawa, Megumi Murata, Tomoka Fujikawa, Kuniko Katagiri, Yoshiko Nagano, Takao Masuda, Madoka Kuramitsu, Shinsuke Nakajima, Jun-Ichi Fujisawa, Kazu Okuma, Poonam Grover, Maureen Kidiga, Hirofumi Akari, Mari Kannagi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-02-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1011104
_version_ 1811162576169467904
author Atsuhiko Hasegawa
Megumi Murata
Tomoka Fujikawa
Kuniko Katagiri
Yoshiko Nagano
Takao Masuda
Madoka Kuramitsu
Shinsuke Nakajima
Jun-Ichi Fujisawa
Kazu Okuma
Poonam Grover
Maureen Kidiga
Hirofumi Akari
Mari Kannagi
author_facet Atsuhiko Hasegawa
Megumi Murata
Tomoka Fujikawa
Kuniko Katagiri
Yoshiko Nagano
Takao Masuda
Madoka Kuramitsu
Shinsuke Nakajima
Jun-Ichi Fujisawa
Kazu Okuma
Poonam Grover
Maureen Kidiga
Hirofumi Akari
Mari Kannagi
author_sort Atsuhiko Hasegawa
collection DOAJ
description A small proportion of human T-cell leukemia virus type-1 (HTLV-1)-infected individuals develop adult T-cell leukemia/lymphoma, a chemotherapy-resistant lymphoproliferative disease with a poor prognosis. HTLV-1-specific cytotoxic T lymphocytes (CTLs), potential anti-tumor/virus effectors, are impaired in adult T-cell leukemia/lymphoma patients. Here, using Japanese monkeys naturally infected with simian T-cell leukemia/T-lymphotropic virus type-1 (STLV-1) as a model, we demonstrate that short-term-cultured autologous peripheral blood mononuclear cells (PBMCs) can serve as a therapeutic vaccine to activate such CTLs. In a screening test, STLV-1-specific CTL activity was detectable in 8/10 naturally STLV-1-infected monkeys. We conducted a vaccine study in the remaining two monkeys with impaired CTL responses. The short-term-cultured PBMCs of these monkeys spontaneously expressed viral antigens, in a similar way to PBMCs from human HTLV-1 carriers. The first monkey was subcutaneously inoculated with three-day-cultured and mitomycin C (MMC)-treated autologous PBMCs, and then boosted with MMC-treated autologous STLV-1-infected cell line cells. The second monkey was inoculated with autologous PBMC-vaccine alone twice. In addition, a third monkey that originally showed a weak STLV-1-specific CTL response was inoculated with similar autologous PBMC-vaccines. In all three vaccinated monkeys, marked activation of STLV-1-specific CTLs and a mild reduction in the STLV-1 proviral load were observed. Follow-up analyses on the two monkeys vaccinated with PBMCs alone indicated that STLV-1-specific CTL responses peaked at 3-4 months after vaccination, and then diminished but remained detectable for more than one year. The significant reduction in the proviral load and the control of viral expression were associated with CTL activation but also diminished 6 and 12 months after vaccination, respectively, suggesting the requirement for a booster. The vaccine-induced CTLs in these monkeys recognized epitopes in the STLV-1 Tax and/or Envelope proteins, and efficiently killed autologous STLV-1-infected cells in vitro. These findings indicated that the autologous PBMC-based vaccine could induce functional STLV-1-specific CTLs in vivo.
first_indexed 2024-04-10T06:32:45Z
format Article
id doaj.art-3ab840225829417bbfff96d171c56a63
institution Directory Open Access Journal
issn 1553-7366
1553-7374
language English
last_indexed 2024-04-10T06:32:45Z
publishDate 2023-02-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Pathogens
spelling doaj.art-3ab840225829417bbfff96d171c56a632023-03-01T05:31:28ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742023-02-01192e101110410.1371/journal.ppat.1011104Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.Atsuhiko HasegawaMegumi MurataTomoka FujikawaKuniko KatagiriYoshiko NaganoTakao MasudaMadoka KuramitsuShinsuke NakajimaJun-Ichi FujisawaKazu OkumaPoonam GroverMaureen KidigaHirofumi AkariMari KannagiA small proportion of human T-cell leukemia virus type-1 (HTLV-1)-infected individuals develop adult T-cell leukemia/lymphoma, a chemotherapy-resistant lymphoproliferative disease with a poor prognosis. HTLV-1-specific cytotoxic T lymphocytes (CTLs), potential anti-tumor/virus effectors, are impaired in adult T-cell leukemia/lymphoma patients. Here, using Japanese monkeys naturally infected with simian T-cell leukemia/T-lymphotropic virus type-1 (STLV-1) as a model, we demonstrate that short-term-cultured autologous peripheral blood mononuclear cells (PBMCs) can serve as a therapeutic vaccine to activate such CTLs. In a screening test, STLV-1-specific CTL activity was detectable in 8/10 naturally STLV-1-infected monkeys. We conducted a vaccine study in the remaining two monkeys with impaired CTL responses. The short-term-cultured PBMCs of these monkeys spontaneously expressed viral antigens, in a similar way to PBMCs from human HTLV-1 carriers. The first monkey was subcutaneously inoculated with three-day-cultured and mitomycin C (MMC)-treated autologous PBMCs, and then boosted with MMC-treated autologous STLV-1-infected cell line cells. The second monkey was inoculated with autologous PBMC-vaccine alone twice. In addition, a third monkey that originally showed a weak STLV-1-specific CTL response was inoculated with similar autologous PBMC-vaccines. In all three vaccinated monkeys, marked activation of STLV-1-specific CTLs and a mild reduction in the STLV-1 proviral load were observed. Follow-up analyses on the two monkeys vaccinated with PBMCs alone indicated that STLV-1-specific CTL responses peaked at 3-4 months after vaccination, and then diminished but remained detectable for more than one year. The significant reduction in the proviral load and the control of viral expression were associated with CTL activation but also diminished 6 and 12 months after vaccination, respectively, suggesting the requirement for a booster. The vaccine-induced CTLs in these monkeys recognized epitopes in the STLV-1 Tax and/or Envelope proteins, and efficiently killed autologous STLV-1-infected cells in vitro. These findings indicated that the autologous PBMC-based vaccine could induce functional STLV-1-specific CTLs in vivo.https://doi.org/10.1371/journal.ppat.1011104
spellingShingle Atsuhiko Hasegawa
Megumi Murata
Tomoka Fujikawa
Kuniko Katagiri
Yoshiko Nagano
Takao Masuda
Madoka Kuramitsu
Shinsuke Nakajima
Jun-Ichi Fujisawa
Kazu Okuma
Poonam Grover
Maureen Kidiga
Hirofumi Akari
Mari Kannagi
Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.
PLoS Pathogens
title Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.
title_full Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.
title_fullStr Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.
title_full_unstemmed Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.
title_short Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.
title_sort vaccination with short term cultured autologous pbmcs efficiently activated stlv 1 specific ctls in naturally stlv 1 infected japanese monkeys with impaired ctl responses
url https://doi.org/10.1371/journal.ppat.1011104
work_keys_str_mv AT atsuhikohasegawa vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT megumimurata vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT tomokafujikawa vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT kunikokatagiri vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT yoshikonagano vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT takaomasuda vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT madokakuramitsu vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT shinsukenakajima vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT junichifujisawa vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT kazuokuma vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT poonamgrover vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT maureenkidiga vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT hirofumiakari vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses
AT marikannagi vaccinationwithshorttermculturedautologouspbmcsefficientlyactivatedstlv1specificctlsinnaturallystlv1infectedjapanesemonkeyswithimpairedctlresponses